• In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. • The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by Regeneron Pharmaceuticals and Bayer. • The post Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test appeared first on MedCity News .

Article Summaries:

  • Ocular Therapeutix has filed an FDA submission following the first of two Phase 3 trials of its wet‑age‑related macular degeneration (AMD) drug, Axpaxli. The study met its primary endpoint, demonstrating that Axpaxli can help maintain vision in patients with wet AMD. The trial compared the new therapy directly with Regeneron‑Bayer’s blockbuster drug Eylea, showing comparable efficacy. The filing signals the company’s intent to pursue regulatory approval and positions Axpaxli as a potential alternative in the competitive wet‑AMD treatment market.

Sources: